François Bénard

USPTO Granted Patents = 12 (Patent Applications = 17)

CIPO Patents = 5 (Patent Applications = 14)

EPO Patents = 8 (Patent Applications = 22)

Average Co-Inventor Count = 5.4

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

7 out of 932

University of British Columbia

patents

7 out of 23

Provincial Health Services Authority

patents

3 out of 61

British Columbia Cancer Agency Branch

Triumf, a Joint Venture

patent

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12472272 - Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer (2025-11-18),

2. 12427209 - Dual mode 18F-labelled theranostic compounds and uses thereof (2025-09-30),

3. 12246076 - Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders (2025-03-11),

4. 11992537 - Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy (2024-05-28),

5. 11884714 - Cyclic peptide analogs of melanocortin and amanitin and methods of making such (2024-01-30),

6. 11661668 - Processes, systems, and apparatus for cyclotron production of technetium-99m (2023-05-30),

7. 11504441 - Radiolabeled compounds targeting the prostate-specific membrane antigen (2022-11-22),

8. 11395857 - Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy (2022-07-26),

9. 10882871 - 18/19F-labelled compounds which target the prostate specific membrane antigen (2021-01-05),

10. 10150804 - Compositions and methods for imaging cancer (2018-12-11),

11. 10039846 - Compositions targeting bradykinin receptor B1 for medical imaging of cancer and other disorders (2018-08-07),

12. 9865367 - Process and apparatus for separation of technetium-99M from molybdate (2018-01-09),

Title: François Bénard: Innovator in Radiolabeled Compounds

Introduction

François Bénard is a prominent inventor based in Vancouver, Canada, known for his significant contributions to the field of radiolabeled compounds. With a total of five patents to his name, he has made remarkable advancements in the imaging and treatment of various disorders.

Latest Patents

Bénard's latest patents include innovative peptidic compounds designed for in vivo imaging of gastrin-releasing peptide receptors (GRPR) and the treatment of GRPR-related disorders. These compounds feature a complex formula that includes various amino acids and radiolabeling groups, showcasing his expertise in peptide chemistry. Another notable patent involves radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues, which are aimed at improving imaging and therapeutic applications.

Career Highlights

Throughout his career, François Bénard has worked with esteemed organizations such as the Provincial Health Services Authority and the University of British Columbia. His work has significantly impacted the medical imaging field, particularly in developing targeted therapies.

Collaborations

Bénard has collaborated with notable colleagues, including Kuo-Shyan Lin and Chengcheng Zhang, further enhancing the scope and impact of his research.

Conclusion

François Bénard's innovative work in radiolabeled compounds has positioned him as a key figure in medical imaging and therapy. His contributions continue to influence advancements in the field, demonstrating the importance of his research.

This text is generated by artificial intelligence and may not be accurate.